Excelsior Sciences applies AI and automated chemistry to simplify small-molecule discovery and accelerate overall drug development.
Excelsior Sciences has raised $70.0M in total funding. The most recent round was Series A. The last funding was announced in December 2025.
Excelsior Sciences's investors include Eli Lilly, Khosla Ventures, Sofinnova Partners, Deerfield Management, Massachusetts Institute of Technology.
Excelsior Sciences is headquartered in New York, United States.
Excelsior Sciences applies AI and automated chemistry to simplify small-molecule discovery and accelerate overall drug development.
Excelsior Sciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Excelsior Sciences — Funding & Investors." VCBacked, December 3, 2025, https://www.vcbacked.co/company/excelsior-sciences. Accessed September 13, 2026.
VCBacked. (2025). Excelsior Sciences — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/excelsior-sciences
{{cite web |title=Excelsior Sciences — Funding & Investors |url=https://www.vcbacked.co/company/excelsior-sciences |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated